Geographic Atrophy Secondary To Age Related Macular Degeneration clinical trials

Explore recruiting geographic atrophy secondary to age related macular degeneration clinical trials.

Recruiting geographic atrophy secondary to age related macular degeneration studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Geographic Atrophy Secondary To Age Related Macular Degeneration trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2, Double-Masked, Placebo-Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

Slovakia, France, Spain, Germany, Hungary, Italy +2 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan in Subjects with Geographic Atrophy Secondary to Age-Related Macular Degeneration

Spain, Netherlands, Italy, Czechia, France, Germany +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2, Randomized, Masked, Placebo-Controlled Study of Subcutaneously Administered ADX-038 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

Germany, Portugal, Italy, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination with Cemdisiran or Cemdisiran Alone in Participants with Geographic Atrophy Secondary to Age-Related Macular Degeneration

France, Austria, Spain, Poland, Italy, Germany +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

An open-label multiple dose safety, tolerability and exploratory efficacy clinical trial of PST-611 in patients with geographic atrophy secondary to age-related macular degeneration

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A randomized, double masked, placebo-controlled, multicenter, dose-range finding study to assess the efficacy and safety of FWY003 in patients with geographic atrophy secondary to age-related macular degeneration

Bulgaria, Romania, Germany, Czechia, Spain, Poland +3 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Geographic Atrophy Secondary To Age Related Macular Degeneration trials by city

Geographic Atrophy Secondary To Age Related Macular Degeneration in Toronto Geographic Atrophy Secondary To Age Related Macular Degeneration in Vancouver Geographic Atrophy Secondary To Age Related Macular Degeneration in Montreal Geographic Atrophy Secondary To Age Related Macular Degeneration in Calgary Geographic Atrophy Secondary To Age Related Macular Degeneration in Edmonton Geographic Atrophy Secondary To Age Related Macular Degeneration in Ottawa Geographic Atrophy Secondary To Age Related Macular Degeneration in Winnipeg Geographic Atrophy Secondary To Age Related Macular Degeneration in Quebec City Geographic Atrophy Secondary To Age Related Macular Degeneration in Hamilton Geographic Atrophy Secondary To Age Related Macular Degeneration in Kitchener Geographic Atrophy Secondary To Age Related Macular Degeneration in London Geographic Atrophy Secondary To Age Related Macular Degeneration in Halifax Geographic Atrophy Secondary To Age Related Macular Degeneration in New York Geographic Atrophy Secondary To Age Related Macular Degeneration in Los Angeles Geographic Atrophy Secondary To Age Related Macular Degeneration in Chicago Geographic Atrophy Secondary To Age Related Macular Degeneration in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease